Home › Interstitial Lung Diseases
Interstitial Lung Diseases clinical trials recruiting in the U.S.
52 studies for Interstitial Lung Diseases are recruiting participants at sites across the United States.
Interstitial lung diseases are a group of diseases that inflame or scar the lungs. Breathing in particles (asbestosis, silicosis) causes some types.
Cities with the most studies
- New York City, NY17 studies
- Philadelphia, PA16 studies
- Los Angeles, CA14 studies
- Kansas City, KS13 studies
- Durham, NC13 studies
- Houston, TX12 studies
- Chicago, IL12 studies
- Charleston, SC11 studies
- Ann Arbor, MI11 studies
- Aurora, CO10 studies
- Boston, MA9 studies
- Rochester, MN9 studies
- Salt Lake City, UT9 studies
- Birmingham, AL8 studies
- Dallas, TX8 studies
- San Francisco, CA8 studies
- Cincinnati, OH7 studies
- Minneapolis, MN7 studies
- Phoenix, AZ7 studies
- Orlando, FL7 studies
- Washington, DC6 studies
- Richmond, VA6 studies
- Winston-Salem, NC6 studies
- Tampa, FL6 studies
- Bend, OR6 studies
- Jacksonville, FL5 studies
- Naples, FL5 studies
- Oklahoma City, OK5 studies
- Cleveland, OH5 studies
- Indianapolis, IN5 studies
- Nashville, TN4 studies
- Greensboro, NC4 studies
- New Orleans, LA4 studies
- Davie, FL4 studies
- Columbus, OH4 studies
- Albuquerque, NM4 studies
- Baltimore, MD4 studies
- St. Louis, MO4 studies
- Rochester, NY4 studies
- Gainesville, FL4 studies
By state
- Alabama8 studies
- Arizona12 studies
- California22 studies
- Colorado12 studies
- Connecticut4 studies
- District of Columbia5 studies
- Florida22 studies
- Georgia3 studies
- Illinois12 studies
- Indiana5 studies
- Kansas13 studies
- Kentucky5 studies
- Louisiana5 studies
- Maryland5 studies
- Massachusetts11 studies
- Michigan16 studies
- Minnesota13 studies
- Mississippi3 studies
- Missouri6 studies
- New Jersey3 studies
- New Mexico4 studies
- New York19 studies
- North Carolina17 studies
- Ohio12 studies
- Oklahoma5 studies
- Oregon8 studies
- Pennsylvania19 studies
- South Carolina12 studies
- Tennessee6 studies
- Texas17 studies
- Utah9 studies
- Virginia8 studies
- Wisconsin3 studies
Recently updated studies
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Nov 13, 2026 · NCT07201922A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Nov 12, 2026 · NCT06968845Collagen-targeted PET Imaging for Early Interstitial Lung Disease
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Nov 12, 2026 · NCT05417776Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
Ages 21 and older · All sexes · Updated Nov 12, 2026 · NCT01915511FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07540988An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07234032Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06911632A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Nov 2, 2026 · NCT07805785Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 27, 2026 · NCT07473700Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07179380Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Oct 26, 2026 · NCT07613099RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT06328777LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Oct 15, 2026 · NCT05798923A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 14, 2026 · NCT07285655Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07372989Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
Recruiting
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT07673237A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 8, 2026 · NCT07175038Pulmonary Fibrosis Foundation Community Registry
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05382572A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07323732A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 11, 2026 · NCT07816185A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 2, 2026 · NCT07333183Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT00258583From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.